LBH 589 success in Phase III Multiple Myeloma trial-Novartis
Novartis has announced that results of a Phase III trial of the investigational compound LBH 589 (panobinostat) in combination with bortezomib and dexamethasone, met the primary endpoint of significantly extending progression-free survival (PFS) in patients with relapsed or relapsed and refractory Multiple Myeloma when compared to bortezomib plus dexamethasone alone. Full results from the PANORAMA-1 (PANobinostat ORAl in Multiple MyelomA) trial, continue to be evaluated and will be presented at an upcoming medical congress and discussed with regulatory authorities worldwide. LBH 589 showed significant clinical benefit bringing it a step closer to becoming the first in its class of anticancer agents to be available to patients with Multiple Myeloma.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins